droxidopa
Modify Date: 2024-01-03 09:28:21
droxidopa structure
|
Common Name | droxidopa | ||
|---|---|---|---|---|
| CAS Number | 23651-95-8 | Molecular Weight | 213.187 | |
| Density | 1.608g/cm3 | Boiling Point | 549.8±50.0 °C at 760 mmHg | |
| Molecular Formula | C9H11NO5 | Melting Point | 232-235° (dec); mp 229-232° (dec) (Ohashi) | |
| MSDS | Chinese USA | Flash Point | 286.3±30.1 °C | |
| Symbol |
GHS07 |
Signal Word | Warning | |
Use of droxidopaDroxidopa(L-DOPS, SM5688) is a synthetic amino acid precursor which acts as a prodrug to the neurotransmitters norepinephrine (noradrenaline) and epinephrine (adrenaline); capable of crossing the protective blood–brain barrierIC50 value: Target: The acute administration of droxidopa in PVL and BDL rats caused a significant and maintained increase in arterial pressure and mesenteric arterial resistance, with a significant decrease of mesenteric arterial and portal blood flow, without changing portal pressure and renal blood flow [1]. L-threo-dihydroxyphenyslerine (Droxidopa) is a pro-drug which has a structure similar to noradrenaline, but with a carboxyl group. It has no pressor effects in this form. It can be administered orally, unlike noradrenaline, and after absorption is converted by the enzyme dopa decarboxylase into noradrenaline thus increasing levels of the neurotransmitter which is identical to endogenous noradrenaline [2]. |
| Name | droxidopa |
|---|---|
| Synonym | More Synonyms |
| Description | Droxidopa(L-DOPS, SM5688) is a synthetic amino acid precursor which acts as a prodrug to the neurotransmitters norepinephrine (noradrenaline) and epinephrine (adrenaline); capable of crossing the protective blood–brain barrierIC50 value: Target: The acute administration of droxidopa in PVL and BDL rats caused a significant and maintained increase in arterial pressure and mesenteric arterial resistance, with a significant decrease of mesenteric arterial and portal blood flow, without changing portal pressure and renal blood flow [1]. L-threo-dihydroxyphenyslerine (Droxidopa) is a pro-drug which has a structure similar to noradrenaline, but with a carboxyl group. It has no pressor effects in this form. It can be administered orally, unlike noradrenaline, and after absorption is converted by the enzyme dopa decarboxylase into noradrenaline thus increasing levels of the neurotransmitter which is identical to endogenous noradrenaline [2]. |
|---|---|
| Related Catalog | |
| References |
| Density | 1.608g/cm3 |
|---|---|
| Boiling Point | 549.8±50.0 °C at 760 mmHg |
| Melting Point | 232-235° (dec); mp 229-232° (dec) (Ohashi) |
| Molecular Formula | C9H11NO5 |
| Molecular Weight | 213.187 |
| Flash Point | 286.3±30.1 °C |
| Exact Mass | 213.063721 |
| PSA | 124.01000 |
| LogP | -0.95 |
| Vapour Pressure | 0.0±1.6 mmHg at 25°C |
| Index of Refraction | 1.692 |
| Storage condition | 2-8C |
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATAACUTE TOXICITY DATA
|
| Symbol |
GHS07 |
|---|---|
| Signal Word | Warning |
| Hazard Statements | H315-H319-H335 |
| Precautionary Statements | P261-P305 + P351 + P338 |
| Hazard Codes | Xi |
| Risk Phrases | 36/37/38 |
| Safety Phrases | 26 |
| RIDADR | NONH for all modes of transport |
| RTECS | VT9626010 |
| HS Code | 29225090 |
|
Application of the BCS biowaiver approach to assessing bioequivalence of orally disintegrating tablets with immediate release formulations.
Eur. J. Pharm. Sci. 64 , 37-43, (2014) The aim of this study was to compare the dissolution profiles of oral disintegrating tablets (ODTs) and immediate release (IR) formulations in order to experimentally validate the regulatory biowaiver... |
|
|
[Acute poisoning of droxidopa: report of a case].
Chudoku. Kenkyu. 26(3) , 244-5, (2013)
|
|
|
The noradrenaline precursor L-DOPS reduces pathology in a mouse model of Alzheimer's disease.
Neurobiol. Aging 33(8) , 1651-63, (2012) Damage to noradrenergic neurons in the locus coeruleus (LC) is a hallmark of Alzheimer's disease (AD) and may contribute to disease progression. In 5xFAD transgenic mice, which accumulate amyloid burd... |
| (-)-(2s,3r)-2-amino-3-hydroxy-3-(3,4-dihydroxyphenyl)propionic acid |
| DL-DOPS |
| DL-threo-Dihydroxyphenylserine |
| L-DOPS |
| 3-dihydroxy-betthreo-dl-tyrosin |
| (2S,3R)-3-(3,4-Dihydroxyphenyl)-2-amino-3-hydroxypropanoic acid |
| 3-dihydroxy-dl-tyrosinethreo-bet |
| DROXIDOPA |
| (2S,3R)-2-Amino-3-(3,4-dihydroxyphenyl)-3-hydroxypropionic Acid |
| Benzeneethanaminium, α-carboxy-β,3,4-trihydroxy-, inner salt, (αS,βS)- |
| (2S,3R)-2-Amino-3-(3,4-dihydroxyphenyl)-3-hydroxypropanoic acid |
| L-threo-DOPS |
| DL-THREO-DOPS |
| L-threo-3,4-Dihydroxyphenylserine |
| (2S,3S)-2-Ammonio-3-(3,4-dihydroxyphenyl)-3-hydroxypropanoate |
| Droxidopa L-threo 3,4-Dihydroxyphenylserine |
| DL-threo-Droxidopa |
| threo-Dopaserine |
| L-threo-3-(3,4-Dihydroxyphenyl)serine |